{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:11:13Z","timestamp":1783635073738,"version":"3.55.0"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,4,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To examine whether the associations of endogenous estrogens and testosterone with breast cancer risk differ between high- and low-risk women, as determined by the Gail model and the Rosner and Colditz model, and by family history of breast cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> We conducted a prospective nested case-control study within the Nurses' Health Study. From 1989 or 1990 until June 2000, blood samples were collected, 418 breast cancer patient cases were identified, and two controls (total n = 817) were matched to each case. We classified women as high or low risk based on their family history of breast cancer, their 5-year Gail risk score, and their 5-year Rosner and Colditz risk score. Multivariate relative risks (RR) and 95% CI were calculated by unconditional logistic regression, adjusting for matching and breast cancer risk factors. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Estrone sulfate was statistically significantly associated with breast cancer risk among women with low (&lt; 1.66%) and high (\u2265 2.52%; 75th percentile) Gail predicted risk (fourth v first quartile RR = 3.6; 95% CI, 1.9 to 7.0; RR = 2.5; 95% CI, 1.2 to 5.1, respectively). Testosterone results were similar across strata of predicted risk, with two times the risk in the fourth (v first) quartile. Estradiol appeared more strongly associated with breast cancer in women with higher predicted risk (RR = 4.5; 95% CI, 2.1 to 9.5) compared with women with lower risk (RR = 2.1; 95% CI, 1.2 to 3.6), but differences were not statistically significant. Results were similar across predicted Rosner and Colditz risk scores. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> These data suggest that higher levels of endogenous estrogens and testosterone are associated with increased breast cancer risk, regardless of predicted risk or family history of breast cancer. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.03.7432","type":"journal-article","created":{"date-parts":[[2006,3,28]],"date-time":"2006-03-28T01:44:18Z","timestamp":1143510258000},"page":"1823-1830","source":"Crossref","is-referenced-by-count":68,"title":["Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer: Does the Association Vary by a Woman's Predicted Breast Cancer Risk?"],"prefix":"10.1200","volume":"24","author":[{"given":"A. Heather","family":"Eliassen","sequence":"first","affiliation":[{"name":"From the Channing Laboratory, Department of Medicine and the Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Missmer","sequence":"additional","affiliation":[{"name":"From the Channing Laboratory, Department of Medicine and the Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[{"name":"From the Channing Laboratory, Department of Medicine and the Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Hankinson","sequence":"additional","affiliation":[{"name":"From the Channing Laboratory, Department of Medicine and the Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.8.606"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601517"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh336"},{"key":"R4","unstructured":"Dorgan JF, Longcope C, Stephenson HE Jr, et al: Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 5:533,1996-539,"},{"key":"R5","unstructured":"Dorgan JF, Stanczyk FZ, Longcope C, et al: Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6:177,1997-181,"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.398"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.17.1292"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.3.190"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009059"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.5.291"},{"key":"R11","unstructured":"Barrett-Connor E, Friedlander NJ, Khaw KT: Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 50:6571,1990-6574,"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116228"},{"key":"R13","unstructured":"Kabuto M, Akiba S, Stevens RG, et al: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9:575,2000-579,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00004"},{"key":"R15","unstructured":"Gordon GB, Bush TL, Helzlsouer KJ, et al: Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 50:3859,1990-3862,"},{"key":"R16","unstructured":"Helzlsouer KJ, Alberg AJ, Bush TL, et al: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18:79,1994-85,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj011"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1879"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.6.359"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.10.950"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.17.1297"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Hankinson SE, London SJ, Chute CG, et al: Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 35:2313,1989-2316,","DOI":"10.1093\/clinchem\/35.12.2313"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2944(70)90002-5"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Mikhail G, Chung HW: Radioimmunoassay of plasma estrogens: Use of polymerized antibodies, in Peron FG, Caldwells BV (eds): Immunological methods in steroid determination . New York, NY, Appleton-Century-Croft, pp 113,1970","DOI":"10.1007\/978-1-4684-6051-3_6"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(70)80053-8"},{"key":"R26","unstructured":"Kinouchi T, Pages L, Horton R: A specific radioimmunossay for testosterone in peripheral plasma. J Lab Clin Med 82:309,1973-316,"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-49-6-851"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(79)80017-3"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.5.358"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00124-0"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1983.10487848"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500161"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0614"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.3.427"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.6.365"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008817018942"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.699"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.18.2251"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.03.7432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:14:37Z","timestamp":1653513277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.03.7432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,20]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,4,20]]}},"alternative-id":["10.1200\/JCO.2005.03.7432"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.03.7432","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,20]]}}}